Table 2.
Aminoglycoside Resistance Genotypes (n= 19)a | Carbapenem Resistance Genotypes (n=8)b | Type of Sample | Source of Specimens | |||
---|---|---|---|---|---|---|
Urine (n=14) | Blood (n=1) | Pus (n=1) | Sputum (n=3) | |||
rmtB 14 (73.6%) |
- blaNDM + blaVIM, 1 (12.5%) - blaVIM, 2 (25%) - blaNDM, 1 (12.5%) |
11 (78.5%) | 0 (0.0%) | 0 (0.0%) | 3 (21.4%) | ICU, 4 (28.6%) Urology, 3 (21.4%) Nephrology, 1 (7.1) Tropical, 2 (14.2%) Outpatient, 4 (28.6%) |
rmtB + armA 1 (7%) | ——– | 1 (100%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | Outpatient, 1 (100%) |
rmtB + aac(6ʹ)lb 1 (7%) | blaNDM, 1 (12.5%) | 0 (0.0%) | 1 (100%) | 0 (0.0%) | 0 (0.0%) | ICU, 1 (100%) |
rmtB + armA + aac(6ʹ)-lb 1 (7%) | — | 1 (100%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | Outpatient, 1 (100%) |
rmtF+ armA 1 (7%) | blaNDM, 1 (12.5%) | 1 (100%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | Outpatient, 1 (100%) |
rmtF 1 (7%) |
blaNDM, 1 (12.5%) | 0 (0.0%) | 0 (0.0%) | 1 (100%) | 0 (0.0%) | Urology, 1 (100%) |
Notes: All parameters are represented as F (%) [frequency and percent]; data were analyzed by the χ2 test. aIndicates the presence of aminoglycoside resistance genes, including the detected methyltransferases (rmtB, armA, and rmtF), either alone or in combination with the only detected aminoglycoside-modifying enzyme, aac(6ʹ)lb. bThe detected metallo-beta-lactamases responsible for carbapenem resistance, including blaNDM and blaVIM, either alone or combined.
Abbreviation: ICU, intensive care unit.